7 completed, 3 active not recruiting, 3 recruiting. 9 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 7, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 6 | Active not recruiting 3, Completed 2, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow abexinostat: new trials by email Literature Review of abexinostat trials Research Report on abexinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma PCI 24781, Temozolomide - Recurrent High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Recruiting | University of Nebraska | 24 | 2023-06-26 | 2026-09-14 |
| A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Abexinostat - Lymphoma, Follicular | Phase 2 | Active not recruiting | Xynomic Pharmaceuticals, Inc. | 87 | 2020-04-22 | 2025-04-10 |
| Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) abexinostat - Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Xynomic Pharmaceuticals, Inc. | 170 | 2020-01-20 | 2025-04-10 |
| A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients Abexinostat - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Xynomic Pharmaceuticals, Inc. | 12 | 2020-01-08 | 2025-04-10 |
| Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Abexinostat, Ibrutinib - Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 15 | 2019-05-29 | 2025-04-25 |
| Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma Abexinostat - Follicular Lymphoma | Phase 2 | Active not recruiting | Xynomic Pharmaceuticals, Inc. | 139 | 2018-08-27 | 2025-04-10 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Abexinostat, Pembrolizumab - Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma | Phase 1 | Completed | Rahul Aggarwal | 35 | 2018-08-20 | 2024-03-22 |
| A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Pazopanib, Abexinostat, Placebo - Renal Cell Carcinoma | Phase 3 | Recruiting | Xynomic Pharmaceuticals, Inc. | 413 | 2018-07-17 | 2025-04-13 |
| Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors PZP115891, PCI-24781 - Metastatic Solid Tumors | Phase 1 | Completed | Pamela Munster | 90 | 2012-06-25 | 2025-03-21 |
| A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer PCI-24781 - Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 | Completed | Pharmacyclics LLC. | 7 | 2010-06-01 | 2013-06-19 |
| PCI-24781 in Combination With Doxorubicin to Treat Sarcoma PCI-24781, Doxorubicin, GCSF - Sarcoma | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 20 | 2009-02-01 | 2025-07-24 |
| Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma PCI-24781 - Lymphoma, Hodgkin Disease | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 55 | 2008-07-01 | 2014-04-07 |
| Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients PCI-24781 - Neoplasms by Site, Lymphoma, Non-hodgkin | Phase 1 | Completed | Pharmacyclics LLC. | 36 | 2007-11-01 | 2011-09-28 |
Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, Mantle-Cell (2) · Multiple Myeloma (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Astrocytoma (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1)
Xynomic Pharmaceuticals, Inc. (5) · Pharmacyclics LLC. (3) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Pamela Munster (1) · Rahul Aggarwal (1) · University of Nebraska (1)
United States (10) · China (4) · Spain (2) · France (1) · Italy (1) · Poland (1) · South Korea (1)
Thorsten Graef, MD (2) · Connie W Batlevi, MD,PhD (1) · Edwin Choy, MD, PhD (1) · Gilles Salles, MD (1) · Nicole A Shonka, MD (1) · Pamela Munster, M.D. (1) · Pamela Munster, MD (1) · Rahul Aggarwal, M.D. (1) · Rahul Aggarwal, MD (1) · Samir Undevia, MD (1) · Yuankai Shi, M.D.; Prof (1)